 | Table 2
Nature Biotechnology 24, 403 - 410 (2006)
doi:10.1038/nbt0406-403
Putting pharmacogenetics into practiceMichael M Hopkins, Dolores Ibarreta, Sibylle Gaisser, Christien M Enzing, Jim Ryan, Paul A Martin, Graham Lewis, Symone Detmar, M Elske van den Akker-van Marle, Adam M Hedgecoe, Paul Nightingale, Marieke Dreiling, K Juliane Hartig, Wieneke Vullings
& Tony Forde | | | | Table 2 Small to medium-sized companies with a minor interest in PGx | | | North American firms | European/rest of world firms | | | | | Amgen (Thousand Oaks, CA, USA) | AdnaGen (Langenhagen, Germany) | | ARCA Discovery (Denver, CO, USA) | Exon Hit (Paris, France) | | Cardinal Health (Dublin, Ohio, USA) | GeneScan Europe (cyp chip) (Freiburg, Germany) | | Ellipsis Biotherapeutics (Toronto, ON, Canada) | Iqur (formerly HepCgen viral genotyping) (Southampton, UK) | | GeneOhm Sciences (San Diego, CA, USA) | IntegraGen (Evry, France) | | InSite Vision (Alameda, CA, USA) | Memorec Biotec (Köln, Germany) | | NeoPharm (Waukega, IL, USA) | PharmaMar (Madrid, Spain) | | Panacea Pharmaceuticals (Gaithersburg, MD, USA) | Solvo Biotechnology (Budapest, Hungary) | | PolyGenyx (Worcester, MA, USA) | | | TriPath Imaging (Burlington, NC, USA) | | |
|
| | | |  |
|
